PL2260020T3 - Hydroksamianowe inhibitory deacetylaz B - Google Patents

Hydroksamianowe inhibitory deacetylaz B

Info

Publication number: PL2260020T3
Authority: PL; Poland
Prior art keywords: hydroxamate; deacetylases; based inhibitors; inhibitors
Prior art date: 2008-03-26

Application number

PL09725624T

Other languages

English (en)

Inventor

Michael Shultz

Christine Hiu-Tung Chen

Young Shin Cho

Lei Jiang

Jianmei Fan

Gang Liu

Dyuti Majumdar

Jianke Li

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-26

Filing date

2009-03-24

Publication date

2015-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2260020(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-24 Application filed by Novartis Ag filed Critical Novartis Ag

2015-01-30 Publication of PL2260020T3 publication Critical patent/PL2260020T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL09725624T 2008-03-26 2009-03-24 Hydroksamianowe inhibitory deacetylaz B PL2260020T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3967408P	2008-03-26	2008-03-26
EP09725624.2A EP2260020B1 (en)	2008-03-26	2009-03-24	Hydroxamate-based inhibitors of deacetylases b
PCT/EP2009/053421 WO2009118305A1 (en)	2008-03-26	2009-03-24	Hydroxamate-based inhibitors of deacetylases b

Publications (1)

Publication Number	Publication Date
PL2260020T3 true PL2260020T3 (pl)	2015-01-30

Family

ID=40591831

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09725624T PL2260020T3 (pl)	2008-03-26	2009-03-24	Hydroksamianowe inhibitory deacetylaz B

Country Status (33)

Country	Link
US (2)	US7943652B2 (pl)
EP (2)	EP2260020B1 (pl)
JP (1)	JP5330498B2 (pl)
KR (1)	KR101252349B1 (pl)
CN (1)	CN102036955B (pl)
AR (1)	AR071072A1 (pl)
AU (1)	AU2009228778B2 (pl)
BR (1)	BRPI0909159A2 (pl)
CA (1)	CA2719477C (pl)
CL (1)	CL2009000727A1 (pl)
CO (1)	CO6531501A2 (pl)
CR (1)	CR11680A (pl)
DO (1)	DOP2010000283A (pl)
EA (1)	EA019033B1 (pl)
EC (1)	ECSP10010497A (pl)
ES (1)	ES2519474T3 (pl)
GE (1)	GEP20125708B (pl)
IL (1)	IL208212A0 (pl)
MA (1)	MA32240B1 (pl)
MX (1)	MX2010010502A (pl)
MY (1)	MY150437A (pl)
NI (1)	NI201000157A (pl)
NZ (1)	NZ588069A (pl)
PA (1)	PA8821301A1 (pl)
PE (1)	PE20091736A1 (pl)
PL (1)	PL2260020T3 (pl)
PT (1)	PT2260020E (pl)
SM (1)	SMP201000116B (pl)
SV (1)	SV2010003677A (pl)
TW (1)	TWI510467B (pl)
UY (1)	UY31738A (pl)
WO (1)	WO2009118305A1 (pl)
ZA (1)	ZA201006474B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011021209A1 (en) *	2009-07-07	2011-02-24	Portsmouth Technologies Llc	Histone deacetylase inhibitors
EP2566333A4 (en)	2010-05-07	2014-04-02	Univ Leland Stanford Junior	IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
CA2862259A1 (en) *	2011-12-29	2013-07-04	Pharmacyclics, Inc.	Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
FR2992317B1 (fr)	2012-06-22	2016-05-13	Diverchim	Procede de preparation de peptides chiraux
EP3179857B1 (en)	2014-08-14	2021-09-08	Mamoun M. Alhamadsheh	Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
CN104910074B (zh) *	2015-03-11	2017-07-14	常州大学	一类含有羟肟酸基团的吡唑类衍生物及其制备方法及用途
KR20170124602A (ko) *	2015-03-13	2017-11-10	포르마 세라퓨틱스 인크.	Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
CN106854189A (zh) *	2015-12-08	2017-06-16	湖南华腾制药有限公司	一种哌嗪化合物的合成方法
US20170273307A1 (en) *	2016-03-28	2017-09-28	Trent University	Silane-based antimicrobial coatings and methods of making and using the same
NZ797281A (en)	2017-02-17	2025-10-31	Eidos Therapeutics Inc	Processes for preparing ag-10, its intermediates, and salts thereof
KR20200135996A (ko)	2018-03-23	2020-12-04	에이도스 테라퓨틱스, 인코포레이티드	Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법
EP4647068A2 (en)	2018-08-17	2025-11-12	Eidos Therapeutics, Inc.	Formulations of ag10
CN113956182B (zh) *	2021-10-11	2023-11-17	杭州师范大学	Hdac/mao-b双重抑制剂及其制备和应用
US20250059184A1 (en) *	2021-12-15	2025-02-20	Delix Therapeutics, Inc.	Imidazopyridine psychoplastogens and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1524747A (en)	1976-05-11	1978-09-13	Ici Ltd	Polypeptide
LU88769I2 (fr)	1982-07-23	1996-11-05	Zeneca Ltd	Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en)	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
US5093330A (en)	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en)	1989-08-11	1991-04-23	Harbor Branch Oceanographic Institution, Inc.	Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en)	1990-05-07	1995-03-07	Ciba-Geigy Corporation	Hydrazones
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en)	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
TW225528B (pl)	1992-04-03	1994-06-21	Ciba Geigy Ag
EP1238986B1 (en)	1992-10-28	2008-06-25	Genentech, Inc.	Use of Vascular endothelial cell growth factor antagonists
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
DE69536015D1 (de)	1995-03-30	2009-12-10	Pfizer Prod Inc	Chinazolinone Derivate
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
DK0836605T3 (da)	1995-07-06	2002-05-13	Novartis Ag	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
SK284073B6 (sk)	1996-04-12	2004-09-08	Warner-Lambert Company	Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
WO1997049688A1 (en)	1996-06-24	1997-12-31	Pfizer Inc.	Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en)	1996-08-30	2000-12-22	Novartis Ag	Method for producing epothilones
DE69724269T2 (de)	1996-09-06	2004-06-09	Obducat Ab	Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de)	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en)	1996-09-13	1998-03-19	Gerald Mcmahon	Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives
CN100344627C (zh)	1996-11-18	2007-10-24	生物技术研究有限公司(Gbf)	埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en)	1997-10-03	1997-12-03	Pharmacia & Upjohn Spa	Polymeric derivatives of camptothecin
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
ATE307123T1 (de)	1998-02-25	2005-11-15	Sloan Kettering Inst Cancer	Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
EP1107964B8 (en)	1998-08-11	2010-04-07	Novartis AG	Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en)	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
UA71587C2 (uk)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1135470A2 (en)	1998-11-20	2001-09-26	Kosan Biosciences, Inc.	Recombinant methods and materials for producing epothilone and epothilone derivatives
EP2016953A3 (en)	1998-12-22	2009-04-15	Genentech, Inc.	Vascular endothelial cell growth factor antagonists and uses thereof
EP1165085B1 (en)	1999-03-30	2006-06-14	Novartis AG	Phthalazine derivatives for treating inflammatory diseases
AR035011A1 (es) *	1999-06-30	2004-04-14	Daiichi Seiyaku Co	Compuestos inhibidores de vla-4
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20060079533A1 (en) *	2001-03-23	2006-04-13	Nieman James A	Methods of treating alzheimer's disease
AR035885A1 (es)	2001-05-14	2004-07-21	Novartis Ag	Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en)	2001-08-07	2001-10-03	Novartis Ag	Organic compounds
CA2473505A1 (en) *	2002-02-07	2003-08-14	Ellen M. Leahy	Novel bicyclic hydroxamates as inhibitors of histone deacetylase
CN1764648A (zh) *	2003-01-13	2006-04-26	安斯泰来制药有限公司	作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
US7135493B2 (en) *	2003-01-13	2006-11-14	Astellas Pharma Inc.	HDAC inhibitor
JP2004345953A (ja)	2003-01-16	2004-12-09	Hiroki Koma	抗菌活性を有する新規な第四級アンモニウム塩化合物およびその製造方法
JP2007501775A (ja)	2003-08-07	2007-02-01	ノバルティスアクチエンゲゼルシャフト	免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
BRPI0413439A (pt)	2003-08-08	2006-10-17	Novartis Ag	combinações compreendendo estaurosporinas
WO2007030455A2 (en)	2005-09-07	2007-03-15	Novartis Ag	Mutations and polymorphisms of hdac10
WO2007030454A2 (en)	2005-09-07	2007-03-15	Novartis Ag	Mutations and polymorphisms of hdac9
ATE554084T1 (de) *	2006-02-07	2012-05-15	Astellas Pharma Inc	N-hydroxyacrylamidverbindungen
US7783564B2 (en)	2006-07-25	2010-08-24	Visa U.S.A. Inc.	Compliance control in a card based program
ES2569477T3 (es)	2006-12-04	2016-05-11	Novartis Ag	Combinación de un inhibidor de HDAC y un antimetabolito
WO2008150782A1 (en)	2007-05-30	2008-12-11	Novartis Ag	Use of hdac inhibitors for the treatment of bone destruction

2009
- 2009-03-24 EP EP09725624.2A patent/EP2260020B1/en active Active
- 2009-03-24 AU AU2009228778A patent/AU2009228778B2/en not_active Ceased
- 2009-03-24 CN CN2009801187972A patent/CN102036955B/zh not_active Expired - Fee Related
- 2009-03-24 MY MYPI20104315 patent/MY150437A/en unknown
- 2009-03-24 EA EA201001524A patent/EA019033B1/ru not_active IP Right Cessation
- 2009-03-24 BR BRPI0909159A patent/BRPI0909159A2/pt not_active Application Discontinuation
- 2009-03-24 EP EP13158259.5A patent/EP2628726A1/en not_active Withdrawn
- 2009-03-24 JP JP2011501196A patent/JP5330498B2/ja not_active Expired - Fee Related
- 2009-03-24 ES ES09725624.2T patent/ES2519474T3/es active Active
- 2009-03-24 WO PCT/EP2009/053421 patent/WO2009118305A1/en not_active Ceased
- 2009-03-24 PL PL09725624T patent/PL2260020T3/pl unknown
- 2009-03-24 GE GEAP200911949A patent/GEP20125708B/en unknown
- 2009-03-24 CA CA2719477A patent/CA2719477C/en not_active Expired - Fee Related
- 2009-03-24 PT PT97256242T patent/PT2260020E/pt unknown
- 2009-03-24 MX MX2010010502A patent/MX2010010502A/es active IP Right Grant
- 2009-03-24 NZ NZ588069A patent/NZ588069A/en not_active IP Right Cessation
- 2009-03-24 KR KR1020107023785A patent/KR101252349B1/ko not_active Expired - Fee Related
- 2009-03-25 PE PE2009000451A patent/PE20091736A1/es not_active Application Discontinuation
- 2009-03-25 CL CL2009000727A patent/CL2009000727A1/es unknown
- 2009-03-25 AR ARP090101062A patent/AR071072A1/es not_active Application Discontinuation
- 2009-03-25 TW TW098109789A patent/TWI510467B/zh not_active IP Right Cessation
- 2009-03-26 UY UY0001031738A patent/UY31738A/es not_active Application Discontinuation
- 2009-03-26 PA PA20098821301A patent/PA8821301A1/es unknown
- 2009-03-26 US US12/411,715 patent/US7943652B2/en not_active Expired - Fee Related
2010
- 2010-09-09 ZA ZA2010/06474A patent/ZA201006474B/en unknown
- 2010-09-16 IL IL208212A patent/IL208212A0/en unknown
- 2010-09-21 CR CR11680A patent/CR11680A/es not_active Application Discontinuation
- 2010-09-22 DO DO2010000283A patent/DOP2010000283A/es unknown
- 2010-09-23 NI NI201000157A patent/NI201000157A/es unknown
- 2010-09-24 SV SV2010003677A patent/SV2010003677A/es not_active Application Discontinuation
- 2010-09-24 EC EC2010010497A patent/ECSP10010497A/es unknown
- 2010-09-29 CO CO10120813A patent/CO6531501A2/es not_active Application Discontinuation
- 2010-10-18 MA MA33262A patent/MA32240B1/fr unknown
- 2010-10-26 SM SM201000116T patent/SMP201000116B/it unknown
2011
- 2011-04-08 US US13/082,956 patent/US8349883B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20110183964A1 (en)	2011-07-28
CN102036955A (zh)	2011-04-27
GEP20125708B (en)	2012-12-10
CA2719477A1 (en)	2009-10-01
AU2009228778A1 (en)	2009-10-01
CN102036955B (zh)	2013-03-27
ZA201006474B (en)	2011-06-29
KR101252349B1 (ko)	2013-04-08
PT2260020E (pt)	2014-10-28
CL2009000727A1 (es)	2010-03-26
EA201001524A1 (ru)	2011-06-30
EP2628726A1 (en)	2013-08-21
BRPI0909159A2 (pt)	2015-11-24
US20090247547A1 (en)	2009-10-01
MY150437A (en)	2014-01-30
JP5330498B2 (ja)	2013-10-30
EP2260020A1 (en)	2010-12-15
US8349883B2 (en)	2013-01-08
DOP2010000283A (es)	2010-10-31
JP2011515437A (ja)	2011-05-19
ECSP10010497A (es)	2010-10-30
AU2009228778B2 (en)	2012-04-19
SV2010003677A (es)	2011-07-05
UY31738A (es)	2009-11-10
KR20100125445A (ko)	2010-11-30
EP2260020B1 (en)	2014-07-23
IL208212A0 (en)	2010-12-30
AR071072A1 (es)	2010-05-26
ES2519474T3 (es)	2014-11-07
NI201000157A (es)	2011-03-29
EA019033B1 (ru)	2013-12-30
CR11680A (es)	2010-11-23
CO6531501A2 (es)	2012-09-28
PA8821301A1 (es)	2010-05-26
PE20091736A1 (es)	2009-11-19
NZ588069A (en)	2012-06-29
US7943652B2 (en)	2011-05-17
SMP201000116B (it)	2011-09-09
TW201004925A (en)	2010-02-01
MA32240B1 (fr)	2011-04-01
TWI510467B (zh)	2015-12-01
MX2010010502A (es)	2010-10-26
WO2009118305A1 (en)	2009-10-01
SMAP201000116A (it)	2011-01-19
CA2719477C (en)	2016-11-08

Publication	Publication Date	Title
ZA201006474B (en)	2011-06-29	Hydroxamate-based inhibitors of deacetylases b
ZA201700326B (en)	2018-04-25	Inhibitors of beta-secretase
EP2318395A4 (en)	2011-10-26	IPA INHIBITORS
ZA200906946B (en)	2011-05-25	Inhibitors of iap
IL199727A0 (en)	2010-04-15	Inhibitors of mek
ZA201006719B (en)	2011-11-30	Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
PL2389352T3 (pl)	2019-10-31	Inhibitory arginazy oraz sposoby zastosowania
ZA201104146B (en)	2012-08-29	Dispersions comprising inhibitors of the hydroxyphenylpyruvate-dioxygenase
IL209488A0 (en)	2011-01-31	Inhibitors of akt activity
IL220187A0 (en)	2012-07-31	Inhibitors of sphingosine kinase
EP2303852A4 (en)	2011-12-28	ACTIVITY INHIBITORS AKT
EP2306825A4 (en)	2011-12-28	HAMMER OF ACT ACTIVITY
ZA201004765B (en)	2011-09-28	Inhibitors of iap
EP2296476A4 (en)	2013-11-06	HEMMER OF BACTERIAL BIOFILMATION
IL217720A0 (en)	2012-03-29	Isoform selective phospholipase d inhibitors
GB0801940D0 (en)	2008-03-12	Inhibitors of lentiviral replication
ZA201102837B (en)	2011-12-28	Phosphodiestarase inhibitors
EP2303277A4 (en)	2011-08-17	HAMMER OF ACT ACTIVITY
EP2303017A4 (en)	2011-06-15	HAMMER OF ACT ACTIVITY
PT2411376E (pt)	2015-09-14	Inibidores de nf-kb
EP2303258A4 (en)	2012-03-14	ACTIVITY INHIBITORS AKT
HK1146059A (en)	2011-05-13	Hydroxamate-based inhibitors of deacetylases b
GB0808286D0 (en)	2008-06-11	Inhibitors of HSP90
AP2717A (en)	2013-07-31	Mono-hydrochloric salts of an inhibitor of histonedeacetylase
GB0908609D0 (en)	2009-06-24	New use of isoQC inhibitors